Developer docs
API playgroundTry for free, no card

Search company profiles

BioXcellerator

Full company profile

uuid000avrl

Namestring
BioXcellerator
Legal namestring
BioXcellerator Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BioXcellerator is a privately held regenerative medicine company that delivers stem cell therapy to patients with orthopedic and sports injuries, autoimmune and degenerative diseases, neurological conditions, chronic inflammatory disorders, and select aesthetic indications. The company is incorporated in Arizona (corporate office in Scottsdale/Phoenix) and operates its primary treatment clinic in Medellín, Colombia, where all clinical procedures are performed; treatments are not available in the United States because the company's advanced cell expansion protocols fall outside current FDA approval pathways. The company is led by CEO Eric Stoffers, CMO Dr. Karolynn Halpert, CSO Matthew Marks, and VP of Sales Jarett Smith, with a total headcount of 11–50.

The company's core technology platform is built around proprietary "BioXcellerator Signature Cells" — mesenchymal stem cells (MSCs) derived from Wharton's jelly umbilical cord tissue, cultured under hypoxic and normoxic conditions to enhance anti-inflammatory and regenerative potency, supplemented by the EVOKE exosome product line. All processing occurs at an on-site ISO-, cGMP-, and FACT-JACIE-aligned laboratory in Medellín. The company operates a wholly owned research subsidiary, BioXscience, that conducts meta-analyses, systematic reviews, and protocol-development work, and the scientific team has published in journals including ISCT Cytotherapy and Frontiers.

BioXcellerator generates revenue through direct-to-consumer medical tourism: patients pay out-of-pocket (no insurance coverage) for customized treatment plans, with a concierge team managing consultation, eligibility screening, travel, accommodations, airport transfers, and follow-up monitoring up to two years post-treatment. Pricing is not publicly disclosed; treatment is positioned as a high-end cash-pay offering for affluent U.S. and international patients, including professional athletes and celebrities, and financing options are available. The company markets primarily through content (blog, social media), patient testimonials, conference participation, and a free consultation funnel. The company has reported thousands of successful patient outcomes and a 97% patient satisfaction rate since initiating treatments in 2018.

Short descriptiontext

BioXcellerator is a privately held regenerative medicine company delivering proprietary Wharton's jelly mesenchymal stem cell and exosome therapies at its Medellín, Colombia clinic, serving U.S. and international patients with orthopedic, autoimmune, neurological, and chronic inflammatory conditions through a direct-to-consumer medical tourism model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapy, regenerative medicine, orthopedic treatments, autoimmune disease therapy, sports injury recovery
Industry4 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Blood and Organ Banks621991
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Regenerative Medicine Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Treatment Services
TypeProfessional Services
Description

Direct patient payments for stem cell therapy treatments at the Medellín, Colombia clinic. Services include personalized treatment plans, concierge coordination (travel, accommodations, transfers), and ongoing follow-up care. Treatment costs are not publicly disclosed and vary based on condition and protocol complexity. Financing options are available for patients.

bioxcellerator.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1Customized treatment plans based on individual patient conditions
ModelOtherBilling cadencePay-as-you-go
Notes

No specific price tiers are published. Each treatment is personalized based on the patient’s medical history, condition, and specific needs. Patient reviews medical history required to determine eligibility and approval for treatment.

bioxcellerator.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 5 records shown
1BioXscience
Description

A subsidiary of BioXcellerator responsible for planning and executing research and innovation activities, including meta-analyses, systematic reviews, and the development of best-practice, patient-specific protocols for regenerative medicine.

bioxcellerator.com
+4 more records
Core offering1 text field

BioXcellerator provides adult stem-cell therapy and regenerative-medicine treatment protocols using its proprietary BioXcellerator Signature Cells, mesenchymal stem cells derived from Wharton's Jelly umbilical cord tissue. Treatments are delivered via intravenous, intrathecal, intra-articular and site-specific injections at its Medellín, Colombia clinic, with adjunctive EVOKE exosome therapy and an on-site cGMP/ISO-certified laboratory and cell bank. The company additionally advances R&D through its research arm BioXscience.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 97% patient satisfaction after post-treatment survey
+1 more record
Product overview1 text field

BioXcellerator is a stem cell therapy and regenerative medicine company offering a portfolio of treatment protocols built on its proprietary Signature Cells technology platform. The core offering consists of high-potency mesenchymal stem cells (MSCs) derived from Wharton's Jelly umbilical cord tissue, available in both hypoxic and normoxic variants, supplemented with MSC exosomes. These are delivered through a suite of named treatment protocols addressing specific conditions including: Fountain of Youth Protocol for Women, Health Optimization and Sports Recovery, Diabetes Treatment, Orthopedic and Sports Injuries, Spine and Disc Conditions, Autoimmune Diseases, Cosmetic and Skin Rejuvenation, Osteoarthritis, Rheumatoid Arthritis, Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis, Sexual Wellness and Erectile Dysfunction, Chronic Pain, Neurological Conditions, Spinal Cord Injuries, and Autism Spectrum Disorder. All treatments are administered at the company's clinic in Medellín, Colombia, with treatments customized per patient based on individual health needs.

Product and service19 records
1BioXcellerator Signature Cells (Wharton's Jelly MSC therapy)
CategoryRegenerative medicine / stem cell therapy
2Health Optimization and Sports Recovery Protocol
CategoryRegenerative medicine / sports recovery
3Fountain of Youth Protocol for Women
CategoryRegenerative medicine / anti-aging and wellness
4Diabetes Stem Cell Treatment
CategoryRegenerative medicine / metabolic disease
5Orthopedic and Sports Injuries Treatment
CategoryRegenerative medicine / orthopedics
6Spine and Disc Conditions Treatment
CategoryRegenerative medicine / spine care
7Autoimmune Diseases Treatment
CategoryRegenerative medicine / autoimmune disease
8Cosmetic and Skin Rejuvenation Treatment
CategoryRegenerative medicine / aesthetics
9Osteoarthritis Stem Cell Treatment
CategoryRegenerative medicine / orthopedics
10Rheumatoid Arthritis Stem Cell Treatment
CategoryRegenerative medicine / autoimmune disease
11Crohn's Disease and Ulcerative Colitis Treatment
CategoryRegenerative medicine / autoimmune disease
12Multiple Sclerosis Stem Cell Treatment
CategoryRegenerative medicine / neurology
13Sexual Wellness and Erectile Dysfunction Treatment
CategoryRegenerative medicine / sexual wellness
14Chronic Pain Stem Cell Treatment
CategoryRegenerative medicine / pain management
15Neurological Conditions Treatment
CategoryRegenerative medicine / neurology
16Spinal Cord Injuries Stem Cell Treatment
CategoryRegenerative medicine / neurology
17Autism Spectrum Disorder Treatment
CategoryRegenerative medicine / neurodevelopmental
18EVOKE Exosome Therapy
CategoryRegenerative medicine / exosome therapy
19BioXscience Research Services
CategoryBiotech research and development
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Regenexx is the largest U.S. orthopedic stem cell and platelet-rich plasma (PRP) network, specializing in autologous MSC/BMC injections for joints, spine, and sports injuries. It directly overlaps BioXcellerator's core orthopedic and sports injury segment but operates within FDA-permitted autologous-only constraints rather than allogeneic Wharton's Jelly MSC.

2Celltex Therapeutics
TypeDirect peer
Description

Celltex operates a Houston-based stem cell bank and a Mexico-based clinic offering autologous MSC therapies to U.S. patients via medical tourism, similar to BioXcellerator's Colombia model. It is a comparable allogeneic MSC + medical tourism peer targeting orthopedic, autoimmune, and degenerative indications.

3DVC Stem
TypeDirect peer
Description

DVC Stem provides adult stem cell therapy via a Grand Cayman clinic, using umbilical cord-derived MSCs for orthopedic, autoimmune, and degenerative conditions - highly overlapping protocol, donor-source, and medical-tourism go-to-market as BioXcellerator.

TypeDirect peer
Description

Swiss Medica runs stem cell clinics in Switzerland, Serbia, and Russia treating orthopedic, neurological, and autoimmune conditions with MSC-based therapies. Multi-site international medical-tourism stem cell clinic directly comparable to BioXcellerator in indication breadth and patient model.

TypeDirect peer
Description

Okyanos is a Bahamas-based regenerative medicine clinic offering adult stem cell therapy for cardiac, orthopedic, and degenerative conditions under a medical-tourism model. Closely overlaps BioXcellerator's indication portfolio and international patient concierge model.

TypeDirect peer
Description

StemGenex is a U.S.-based stem cell treatment provider marketing adipose- and bone-marrow-derived therapies for a broad indication set. Direct overlap in indications (MS, autoimmune, orthopedic) and direct-to-consumer marketing approach; comparable allogeneic-adjacent treatment model.

7Panama Stem Cell Center
TypeDirect peer
Description

Panama Stem Cell Center treats U.S. and international patients at a Panama City clinic with MSC-based therapies for orthopedic, autoimmune, and degenerative conditions. Closely overlapping Latin America medical-tourism stem cell clinic peer with similar protocols and pricing posture.

TypeEmerging player
Description

Global Stem Cells is a stem cell treatment group running clinics and educational/advisory programs targeting patients with degenerative diseases across multiple countries. Less brand-saturated than BioXcellerator but overlapping indication breadth and medical-tourism positioning.

9CelluGen Biotech
TypeEmerging player
Description

CelluGen offers exosome-based regenerative therapies alongside stem cell products, adjacent to BioXcellerator's EVOKE exosome line and Signature Cells. Overlaps as an emerging exosome/MSC competitor with direct-to-patient marketing.

TypeOthers
Description

Innovative Medicine operates as a regenerative-medicine clinic aggregator and concierge referral service that routes U.S. patients to international stem cell providers. Comparable distribution role to the medical-tourism concierge channel BioXcellerator uses, but competes for the same inbound patients.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioXcellerator

Regenerative Medicine Servicesbioxcellerator.com

BioXcellerator is a privately held regenerative medicine company delivering proprietary Wharton's jelly mesenchymal stem cell and exosome therapies at its Medellín, Colombia clinic, serving U.S. and international patients with orthopedic, autoimmune, neurological, and chronic inflammatory conditions through a direct-to-consumer medical tourism model.

What BioXcellerator does

BioXcellerator is a privately held regenerative medicine company that delivers stem cell therapy to patients with orthopedic and sports injuries, autoimmune and degenerative diseases, neurological conditions, chronic inflammatory disorders, and select aesthetic indications. The company is incorporated in Arizona (corporate office in Scottsdale/Phoenix) and operates its primary treatment clinic in Medellín, Colombia, where all clinical procedures are performed; treatments are not available in the United States because the company's advanced cell expansion protocols fall outside current FDA approval pathways. The company is led by CEO Eric Stoffers, CMO Dr. Karolynn Halpert, CSO Matthew Marks, and VP of Sales Jarett Smith, with a total headcount of 11–50.

The company's core technology platform is built around proprietary "BioXcellerator Signature Cells" — mesenchymal stem cells (MSCs) derived from Wharton's jelly umbilical cord tissue, cultured under hypoxic and normoxic conditions to enhance anti-inflammatory and regenerative potency, supplemented by the EVOKE exosome product line. All processing occurs at an on-site ISO-, cGMP-, and FACT-JACIE-aligned laboratory in Medellín. The company operates a wholly owned research subsidiary, BioXscience, that conducts meta-analyses, systematic reviews, and protocol-development work, and the scientific team has published in journals including ISCT Cytotherapy and Frontiers.

BioXcellerator generates revenue through direct-to-consumer medical tourism: patients pay out-of-pocket (no insurance coverage) for customized treatment plans, with a concierge team managing consultation, eligibility screening, travel, accommodations, airport transfers, and follow-up monitoring up to two years post-treatment. Pricing is not publicly disclosed; treatment is positioned as a high-end cash-pay offering for affluent U.S. and international patients, including professional athletes and celebrities, and financing options are available. The company markets primarily through content (blog, social media), patient testimonials, conference participation, and a free consultation funnel. The company has reported thousands of successful patient outcomes and a 97% patient satisfaction rate since initiating treatments in 2018.

BioXcellerator firmographics

Firmographics
Name
BioXcellerator
Legal name
BioXcellerator Inc.
Website
https://bioxcellerator.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
BioXcellerator is a privately held regenerative medicine company delivering proprietary Wharton's jelly mesenchymal stem cell and exosome therapies at its Medellín, Colombia clinic, serving U.S. and international patients with orthopedic, autoimmune, neurological, and chronic inflammatory conditions through a direct-to-consumer medical tourism model.
Ownership category
akta.pro rank

BioXcellerator industry classification

Industry
Product category
Regenerative Medicine Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Blood and Organ Banks (621991), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAE
Cell & Tissue Banking (biobanking, cord blood/tissue)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell therapy
  • Regenerative medicine
  • Orthopedic treatments
  • Autoimmune disease therapy
  • Sports injury recovery

Where BioXcellerator is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

BioXcellerator business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Medical Treatment Services: Direct patient payments for stem cell therapy treatments at the Medellín, Colombia clinic. Services include personalized treatment plans, concierge coordination (travel, accommodations, transfers), and ongoing follow-up care. Treatment costs are not publicly disclosed and vary based on condition and protocol complexity. Financing options are available for patients.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustomized treatment plans based on individual patient conditions

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

BioXcellerator product offering

Product offering

Core offering

BioXcellerator provides adult stem-cell therapy and regenerative-medicine treatment protocols using its proprietary BioXcellerator Signature Cells, mesenchymal stem cells derived from Wharton's Jelly umbilical cord tissue. Treatments are delivered via intravenous, intrathecal, intra-articular and site-specific injections at its Medellín, Colombia clinic, with adjunctive EVOKE exosome therapy and an on-site cGMP/ISO-certified laboratory and cell bank. The company additionally advances R&D through its research arm BioXscience.

Product overview

BioXcellerator is a stem cell therapy and regenerative medicine company offering a portfolio of treatment protocols built on its proprietary Signature Cells technology platform. The core offering consists of high-potency mesenchymal stem cells (MSCs) derived from Wharton's Jelly umbilical cord tissue, available in both hypoxic and normoxic variants, supplemented with MSC exosomes. These are delivered through a suite of named treatment protocols addressing specific conditions including: Fountain of Youth Protocol for Women, Health Optimization and Sports Recovery, Diabetes Treatment, Orthopedic and Sports Injuries, Spine and Disc Conditions, Autoimmune Diseases, Cosmetic and Skin Rejuvenation, Osteoarthritis, Rheumatoid Arthritis, Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis, Sexual Wellness and Erectile Dysfunction, Chronic Pain, Neurological Conditions, Spinal Cord Injuries, and Autism Spectrum Disorder. All treatments are administered at the company's clinic in Medellín, Colombia, with treatments customized per patient based on individual health needs.

Differentiator

Problem solved

Functional benefit

Brands

  • BioXscience: A subsidiary of BioXcellerator responsible for planning and executing research and innovation activities, including meta-analyses, systematic reviews, and the development of best-practice, patient-specific protocols for regenerative medicine.
  • BioXcellerator Signature Cells
  • EVOKE Exosomes (Extracellular Vesicles Optimizing Key Enhancements)
  • Fountain of Youth Protocol for Women
  • Health Optimization and Sports Recovery

Products and services

  • BioXcellerator Signature Cells (Wharton's Jelly MSC therapy)
  • Health Optimization and Sports Recovery Protocol
  • Fountain of Youth Protocol for Women
  • Diabetes Stem Cell Treatment
  • Orthopedic and Sports Injuries Treatment
  • Spine and Disc Conditions Treatment
  • Autoimmune Diseases Treatment
  • Cosmetic and Skin Rejuvenation Treatment
  • Osteoarthritis Stem Cell Treatment
  • Rheumatoid Arthritis Stem Cell Treatment
  • Crohn's Disease and Ulcerative Colitis Treatment
  • Multiple Sclerosis Stem Cell Treatment
  • Sexual Wellness and Erectile Dysfunction Treatment
  • Chronic Pain Stem Cell Treatment
  • Neurological Conditions Treatment
  • Spinal Cord Injuries Stem Cell Treatment
  • Autism Spectrum Disorder Treatment
  • EVOKE Exosome Therapy
  • BioXscience Research Services

Quantifiable outcome

  • 97% patient satisfaction after post-treatment survey
  • +1 more outcomes

Companies that use BioXcellerator

Customer profile

Named customers10 records

Segments7 records

Ideal customer profiles1 record

BioXcellerator technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

BioXcellerator partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

BioXcellerator competitors and assessment

Company assessment

Direct peers

  • Regenexx: Regenexx is the largest U.S. orthopedic stem cell and platelet-rich plasma (PRP) network, specializing in autologous MSC/BMC injections for joints, spine, and sports injuries. It directly overlaps BioXcellerator's core orthopedic and sports injury segment but operates within FDA-permitted autologous-only constraints rather than allogeneic Wharton's Jelly MSC.
  • Celltex Therapeutics: Celltex operates a Houston-based stem cell bank and a Mexico-based clinic offering autologous MSC therapies to U.S. patients via medical tourism, similar to BioXcellerator's Colombia model. It is a comparable allogeneic MSC + medical tourism peer targeting orthopedic, autoimmune, and degenerative indications.
  • DVC Stem: DVC Stem provides adult stem cell therapy via a Grand Cayman clinic, using umbilical cord-derived MSCs for orthopedic, autoimmune, and degenerative conditions - highly overlapping protocol, donor-source, and medical-tourism go-to-market as BioXcellerator.
  • Swiss Medica: Swiss Medica runs stem cell clinics in Switzerland, Serbia, and Russia treating orthopedic, neurological, and autoimmune conditions with MSC-based therapies. Multi-site international medical-tourism stem cell clinic directly comparable to BioXcellerator in indication breadth and patient model.
  • Okyanos Heart Institute: Okyanos is a Bahamas-based regenerative medicine clinic offering adult stem cell therapy for cardiac, orthopedic, and degenerative conditions under a medical-tourism model. Closely overlaps BioXcellerator's indication portfolio and international patient concierge model.
  • StemGenex: StemGenex is a U.S.-based stem cell treatment provider marketing adipose- and bone-marrow-derived therapies for a broad indication set. Direct overlap in indications (MS, autoimmune, orthopedic) and direct-to-consumer marketing approach; comparable allogeneic-adjacent treatment model.
  • Panama Stem Cell Center: Panama Stem Cell Center treats U.S. and international patients at a Panama City clinic with MSC-based therapies for orthopedic, autoimmune, and degenerative conditions. Closely overlapping Latin America medical-tourism stem cell clinic peer with similar protocols and pricing posture.

Emerging players

  • Global Stem Cells: Global Stem Cells is a stem cell treatment group running clinics and educational/advisory programs targeting patients with degenerative diseases across multiple countries. Less brand-saturated than BioXcellerator but overlapping indication breadth and medical-tourism positioning.
  • CelluGen Biotech: CelluGen offers exosome-based regenerative therapies alongside stem cell products, adjacent to BioXcellerator's EVOKE exosome line and Signature Cells. Overlaps as an emerging exosome/MSC competitor with direct-to-patient marketing.

Others

  • Innovative Medicine: Innovative Medicine operates as a regenerative-medicine clinic aggregator and concierge referral service that routes U.S. patients to international stem cell providers. Comparable distribution role to the medical-tourism concierge channel BioXcellerator uses, but competes for the same inbound patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BioXcellerator social profiles

Digital presence

BioXcellerator financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioXcellerator leadership team

Management profile

Number of profiles

Profiles7 records

BioXcellerator subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

BioXcellerator funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioXcellerator M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioXcellerator

What does BioXcellerator do?

BioXcellerator provides adult stem-cell therapy and regenerative-medicine treatment protocols using its proprietary BioXcellerator Signature Cells, mesenchymal stem cells derived from Wharton's Jelly umbilical cord tissue. Treatments are delivered via intravenous, intrathecal, intra-articular and site-specific injections at its Medellín, Colombia clinic, with adjunctive EVOKE exosome therapy and an on-site cGMP/ISO-certified laboratory and cell bank. The company additionally advances R&D through its research arm BioXscience.

Is BioXcellerator a public or private company?

BioXcellerator is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioXcellerator founded?

BioXcellerator was founded in 2018. It employs 11 to 50 people.

Where is BioXcellerator based?

BioXcellerator is headquartered in Scottsdale, United States, in the North America region.

How does BioXcellerator make money?

One revenue line is on record: medical Treatment Services.

Who are BioXcellerator's main competitors?

Direct peers on record are Regenexx, Celltex Therapeutics, DVC Stem, Swiss Medica, Okyanos Heart Institute, StemGenex and Panama Stem Cell Center. Emerging players are Global Stem Cells and CelluGen Biotech. Innovative Medicine is listed as an others.

Does BioXcellerator have an API?

No public API is recorded for BioXcellerator.

What industry is BioXcellerator in?

BioXcellerator's product category is Regenerative Medicine Services. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageBioXcellerator to Address Congressional Veterans Care Forum on Future of Regenerative Medicine for America's VeteransBioXcellerator Co-Founder and CEO Eric Stoffers will participate in the Congressional Veterans Care Forum in Washington, D.C., joining members of Congress, veterans, and healthcare leaders to discuss the responsible expansion of regenerative medicine for veterans. The forum, hosted by Congressmen Eli Crane and Derrick Van Orden, will explore treatments for conditions disproportionately affecting veterans including orthopedic injuries, traumatic brain injuries, and chronic pain. BioXcellerator, which has treated thousands of patients from over 60 countries, views this participation as reflecting the growing role of real-world clinical experience in national regenerative medicine conversations.Business Wire BlogBioXcellerator to Address Congressional Veterans Care Forum on Future of Regenerative Medicine for America's VeteransBioXcellerator CEO Eric Stoffers will participate in the Congressional Veterans Care Forum in Washington D.C., joining members of Congress, veterans, and healthcare leaders to discuss the expansion of regenerative medicine for America's veterans. The bipartisan forum, hosted by Congressmen Eli Crane and Derrick Van Orden, will explore treatments for conditions disproportionately affecting military veterans including orthopedic injuries, traumatic brain injuries, neurological conditions, and chronic pain. The event reflects the growing role of real-world clinical experience in national conversations about regenerative medicine, with BioXcellerator bringing former servicemen it has treated to share their results.YahooEagles News: Cam Jurgens travels to South America in search of healingCam Jurgens of the Philadelphia Eagles traveled to Colombia for a 'health reset week' at bioXcellerator to seek alternative healing methods following injury. The event highlights ongoing athlete use of international stem-cell therapy centers due to U.S. restrictions. No further developments about the event are provided.HuntscanlonRudish Health Assists bioXcellerator with Chief Revenue Officer SearchRudish Health has recruited Beverly Tanabe as the new chief revenue officer for bioXcellerator. Tanabe brings 15 years of experience in driving revenue-generating elements and previously served as CRO at Genomind. This appointment is part of a broader industry trend of companies seeking experienced leaders to oversee go-to-market strategies.PR NewswireTreating COVID-19: BioXcellerator Granted Regulatory Approval for Major Clinical Trial on Stem Cell TherapyBioXcellerator announced it is launching a clinical trial on stem cell therapy as a treatment for acute COVID-19 symptoms after receiving regulatory approval from Colombia's INVIMA on October 5, 2020, marking the first such approval granted in Colombia for regenerative medicine research. The study, conducted in partnership with Clinica Somer, will evaluate the effectiveness of mesenchymal stem cells in treating severe COVID-19 cases that develop acute respiratory distress syndrome, which has mortality rates as high as 40%. The company positions this as a milestone that places it among a worldwide consortium of researchers working to combat the pandemic, with additional studies proposed in various stages of regulatory review globally.